# Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

> **NCT00034151** · PHASE2 · COMPLETED · sponsor: **Achieve Life Sciences** · enrollment: 52 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** S-8184 Paclitaxel Injectable Emulsion

## Key facts

- **NCT ID:** NCT00034151
- **Lead sponsor:** Achieve Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2009-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034151, "Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00034151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*